Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe

Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3gMXgTe
via IFTTT